P327 Responsiveness of rituximab in refractory cases of inflammatory myopathies

Idiopathic inflammatory myopathies (IIM) are the disease with progressive weakness and evidence of muscle necrosis and inflammation. Most patients respond well to high dose steroid and subsequent immunosuppressants, but some are refractory to traditional regimens for immunosuppression. Rituximab (RTX), a chimeric monoclonal antibody targeting CD20 B cells, can be an option for refractory cases of IIM. We are to report our result of RTX treatment in those cases. Ten patients were enrolled, who were treated with RTX because they did not fully respond to prior medications.

Source: Neuromuscular Disorders - October 1, 2023 Category: Neurology Authors: J. No, Y. Park Source Type: research